However, a new study has shown that two drugs - lecanemab and donanemab - could help patients stay independent by approximately 10-13 months in the early stage. Usually, in Alzheimer's disease ...

New research shows that lecanemab and donanemab can slow cognitive decline and extend patients' independence in daily activities. But with high costs and risks, are these treatments truly ...

Additionally, a cost-effective analysis of lecanemab in Canada will be presented. "The data presented at AAN highlights not only the breadth and depth of real-world experience with lecanemab ...

Since receiving approval from the U.S. Food and Drug Administration in 2023 as only the second Alzheimer’s-modifying drug, sales of lecanemab, marketed as Leqembi, have consistently increased ...

Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they slowed the progression of memory-robbing illness in its early stages by up to 35 ...

Following CHMP's reaffirmation, after having considered the additional information requested by the European Commission (EC), the EC will resume the decision-making process for lecanemab's ...

Here we go again. With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with their next Alzheimer's disease therapy lecanemab, which is now fully filed with the FDA.

Eisai Europe Ltd. and Biogen Idec Ltd. announced that NICE will convene a third appraisal committee meeting for the ongoing evaluation of Leqembi® (lecanemab). Lecanemab was authorised by the MHRA for ...

After the commercial failure of Aduhelm, hopes have been high for lecanemab, an amyloid-targeting drug from Eisai and Biogen that issued a preliminary report of a highly successful Phase 3 trial ...

Following CHMP’s reaffirmation, after having considered the additional information requested by the European Commission, the EC will resume the decision-making process for lecanemab’s ...

Eisai Co. and U.S. partner Biogen Inc. developed lecanemab, the first medication designed to remove a protein believed to cause Alzheimer's, a type of dementia. It will be commercially available ...